Building Trust In CER Results Is Among Key Challenges, CMS' Jacques Says
Executive Summary
BALTIMORE - Building trust in the results of comparative effectiveness research is going to be a key challenge for anyone looking to use that data going forward, CMS' Louis Jacques told attendees at the Horizons 2010 conference
You may also be interested in...
Senate Considers Revised Comparative Effectiveness Plan In Reform Bill
Comparative effectiveness research led by a non-government institute with funding from public and private sources, as envisioned by Sen. Max Baucus, D-Mont., is among the provisions for health care reform that are being debated by the Senate, but some changes to CER provisions were made as the bill moved from the Finance Committee to its current iteration on the Senate floor
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials